Parikh, Aparna R.
Leshchiner, Ignaty http://orcid.org/0000-0001-8942-9265
Elagina, Liudmila
Goyal, Lipika
Levovitz, Chaya
Siravegna, Giulia
Livitz, Dimitri http://orcid.org/0000-0003-2528-1446
Rhrissorrakrai, Kahn
Martin, Elizabeth E.
Van Seventer, Emily E.
Hanna, Megan
Slowik, Kara
Utro, Filippo http://orcid.org/0000-0003-3226-7642
Pinto, Christopher J.
Wong, Alicia
Danysh, Brian P.
de la Cruz, Ferran Fece http://orcid.org/0000-0003-2694-4838
Fetter, Isobel J.
Nadres, Brandon http://orcid.org/0000-0002-4690-5978
Shahzade, Heather A.
Allen, Jill N.
Blaszkowsky, Lawrence S.
Clark, Jeffrey W.
Giantonio, Bruce
Murphy, Janet E.
Nipp, Ryan D.
Roeland, Eric
Ryan, David P.
Weekes, Colin D.
Kwak, Eunice L.
Faris, Jason E.
Wo, Jennifer Y.
Aguet, François http://orcid.org/0000-0001-9414-300X
Dey-Guha, Ipsita
Hazar-Rethinam, Mehlika
Dias-Santagata, Dora
Ting, David T. http://orcid.org/0000-0002-3261-2322
Zhu, Andrew X.
Hong, Theodore S.
Golub, Todd R. http://orcid.org/0000-0003-0113-2403
Iafrate, A. John
Adalsteinsson, Viktor A.
Bardelli, Alberto
Parida, Laxmi http://orcid.org/0000-0002-7872-5074
Juric, Dejan http://orcid.org/0000-0003-2983-7704
Getz, Gad http://orcid.org/0000-0002-0936-0753
Corcoran, Ryan B. http://orcid.org/0000-0001-8173-5778
Article History
Received: 28 February 2019
Accepted: 25 July 2019
First Online: 9 September 2019
Change Date: 19 November 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: A.R.P. is a consultant/advisory board member for PureTech, Driver, Foundation Medicine and Eisai, and has institutional research funding from Array, Plexxikon, Guardant, BMS, MacroGenics, Genentech, Novartis, OncoMed and Tolero. L.G. is a consultant/advisory board member for Debiopharm, H3 Biomedicine and Pieris Pharmaceuticals, and a steering committee member for Agios Pharmaceuticals, Taiho Pharmaceuticals and Debiopharm. E.R. is an advisory board member/consultant for Helsinn, Heron, BASF, American Imaging Management, Napo, Immuneering and Vector Oncology. D.P.R. serves on advisory boards for MPM Capital, Gritstone Oncology, Oncorus and TCR2, has equity in MPM Capital and Acworth Pharmaceuticals, and serves as an author for Johns Hopkins University Press, UpToDate and McGraw Hill. C.D.W. is a consultant for Celgene. J.E.F. is an employee at Novartis, has served as an advisory board member/consultant for Merrimack and N-of-One, and received research funding from Novartis, Roche/Genentech, Agios, Takeda, Sanofi, Celgene and Exelixis, as well as travel support from Roche/Genentech. E.L.K. is an employee of Novartis. M.H.-R. is an employee of Forma Therapeutics. D.T.T. is a consultant/advisory board member for Merrimack, Roche Ventana and EMD Millipore–Sigma, is a founder and has equity in PanTher Therapeutics, and receives research funding from ACD-Biotechne. A.X.Z. is a consultant/advisor for AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Exelixis, Merck, Novartis and Roche/Genentech, and received research funding from Bayer, Bristol-Myers Squibb, Eli Lilly, Merck and Novartis. T.S.H. is a consultant/advisory board member for Merck and EMD Serono, and received research support from Taiho, AstraZeneca, Bristol-Myers Squibb, Mobetron and Ipsen. A.J.I. is a consultant for DebioPharm, Chugai and Roche, received research support from Sanofi and has equity in ArcherDX. T.R.G. is or has been a consultant/advisor for Foundation Medicine, GlaxoSmithKline, Sherlock Biosciences and Forma Therapeutics, and holds equity in Sherlock Biosciences and Forma Therapeutics. R.B.C. is a consultant/advisory board member for Amgen, Array Biopharma, Astex Pharmaceuticals, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Fog Pharma, Fount Therapeutics, Genentech, LOXO, Merrimack, N-of-One, Novartis, nRichDX, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Taiho and Warp Drive Bio, holds equity in Avidity Biosciences, C4 Therapeutics, Fount Therapeutics, nRichDX and Revolution Medicines, and has received research funding from Asana, AstraZeneca and Sanofi. D.J. is an advisor/consultant for Novartis, Genentech, Eisai, Ipsen and EMD Serono, and receives research support from Novartis, Genentech, Eisai, EMD Serono, Takeda, Celgene and Placon. G.G. receives research funds from IBM and Pharmacyclics, and is an inventor on patent applications related to MuTect, ABSOLUTE, and POLYSOLVER. K.R., F.U., C.L. and L.P. are listed as co-inventors on a patent application currently pending review at the USPTO. I.L. L.E., D.L., E.E.V.S., E.E.M., M.H., K.S., C.J.P., A.W., B.P.D., F.F.d.l.C., I.J.F., B.N., H.A.S., J.N.A., L.S.B., J.W.C., B.G., J.E.M., R.D.N., F.A., I.D.-G., D.D.-S. and V.A.A. declare no competing interests.